Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70624 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Lei Mao und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinica…. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Antineoplastic Combined Chemotherapy Protocols, Molecular Targeted Therapy, Maintenance Chemotherapy. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of China Youth Science Fund Project, Guangdong Province Basic and Applied Basic Research Fund Project, Youth S&T Talent Support Programme of Guangdong Provincial Association for Science and Technology and Young Science and Technology Talent Support Program of Gu….
Themen: Onkologische Pflege
Abstract (Originalsprache)
Maintenance therapy (MT) and targeted drugs have improved the survival of patients with high‐risk rhabdomyosarcoma (RMS) in clinical trials. However, there are limited data concerning targeted drugs and oral chemotherapy for MT in pediatric patients with very‐high‐risk (VHR) and high‐risk (HR) RMS. Here, we evaluated the safety and effectiveness of these regimens and aimed to identify circulating tumor DNA (ct‐DNA) markers associated with prognosis. We retrospectively retrieved data for 102 pediatric patients with VHR or HR RMS who underwent MT at Sun Yat‐sen University Cancer Center from January 2011 to March 2025 involving targeted drugs plus oral chemotherapy (subgroup 1); targeted drugs (subgroup 2); and oral chemotherapy (subgroup 3). Ct‐DNA markers were examined throughout treatment and at follow‐up. Subgroups 1 and 2 comprised 14 and seven VHR RMS patients, respectively, and subgroup 3 consisted of 39 VHR and 42 HR RMS patients. With a median follow‐up of 32 months, no significant differences among subgroups in duration of remission ( p = 0.56) or 2‐year event‐free survival ( p = 0.78) were observed. PAX–FOXO1 fusion ( p = 0.01), CDK4 mutation ( p = 0.02), and TP53 mutation ( p = 0.02) were independently associated with unfavorable duration of remission. No grade 3 or higher treatment‐related adverse events were observed. MT with targeted drugs shows comparable efficacy in VHR and HR pediatric RMS patients, with manageable adverse reactions. Longitudinal ct‐DNA testing could guide treatment decision‐making and prognostic stratification for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Canc…
- Department of Pediatric, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
- Department of Pediatrics, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
ORCID-Profile: Lei Mao, Zijun Zhen, Yizhuo Zhang
Förderung
- Natural Science Foundation of China Youth Science Fund Project
- Guangdong Province Basic and Applied Basic Research Fund Project
- Youth S&T Talent Support Programme of Guangdong Provincial Association for Science and Technology and Young Science and Technology Talent Support Program of Gu…
- National Natural Science Foundation of China
Zitieren
APA
Mao, L., Mai, Y., Lu, S., Sun, F., Wang, J., Zhu, J., Huang, J., Song, M., Zhang, Y., Zhen, Z., Wu, Y., Lin, X., Meng, C., Zhang, Y., & Que, Y. (2026). Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety. International Journal of Cancer. https://doi.org/10.1002/ijc.70624
Vancouver
Mao L, Mai Y, Lu S, Sun F, Wang J, Zhu J, et al. Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety. International Journal of Cancer. 2026. doi:10.1002/ijc.70624
BibTeX
@article{Mao2026,
author = {Mao, Lei and Mai, Yumiao and Lu, Suying and Sun, Feifei and Wang, Juan and Zhu, Jia and Huang, Junting and Song, Mengjia and Zhang, Yu and Zhen, Zijun and Wu, Yanpeng and Lin, Xiheng and Meng, Cuiping and Zhang, Yizhuo and Que, Yi},
title = {Targeted Therapy and Oral Chemotherapy as Maintenance Treatment in Pediatric Very‐High‐Risk and High‐Risk Rhabdomyosarcoma: A Retrospective Study of Efficacy and Safety},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70624}
}
EUVIMED